Current Report Filing (8-k)
27 June 2019 - 6:31AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
June 26, 2019
PURE
BIOSCIENCE, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-14468
|
|
33-0530289
|
(State
or Other Jurisdiction
of Incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
1725
Gillespie Way
El
Cajon, California
|
|
92020
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
(619)
596-8600
(Registrant’s
Telephone Number, Including Area Code)
Not
applicable
(Former
Name or Former Address If Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b)
of the Act: None. The Registrant’s common stock is traded on the OTC.
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
1.01
|
Entry
into a Material Definitive Agreement.
|
On June 9, 2019, PURE Bioscience, Inc.
(the “Company” or “PURE”) entered into an initial five-year manufacturing supply agreement with Intercon
Chemical Company (ICC) with a three-year renewal term option (the “Manufacturing Supply Agreement”). The agreement
consists of manufacturing, packaging, and distribution of PURE’s SDC-based products. The Manufacturing Supply Agreement provides:
|
(i)
|
ICC
licenses
PURE’s patents and technology know-how for the non-exclusive manufacture of PURE’s SDC-based
products.
|
|
|
|
|
(ii)
|
ICC
will invest in
plant improvements to allow for expanded SDC production.
|
|
|
|
|
(iii)
|
ICC’s
R&D
team will collaborate on SDC product line development.
|
The Manufacturing Supply Agreement may be terminated
by mutual written consent, or by either party upon the material breach of the terms of the agreement by the other party.
The foregoing description of the Manufacturing
Supply Agreement is only a summary of the material terms of such agreement, does not purport to be complete and is qualified in
its entirety by reference to the full text of the Manufacturing Supply Agreement, which is filed as Exhibit 10.1 to this Current
Report on Form 8-K and incorporated by reference herein.
Item
9.01
|
Financial
Statements and Exhibits.
|
(d)
Exhibits
*Certain
portions of this exhibit have been redacted to preserve confidentiality. The registrant hereby undertakes to provide further information
regarding such redacted information to the Commission upon request.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
PURE BIOSCIENCE, INC.
|
|
|
|
Dated:
June 26, 2019
|
By:
|
/s/
Henry R. Lambert
|
|
|
Henry
R. Lambert
|
|
|
Chief
Executive Officer
|
PURE Bioscience (PK) (USOTC:PURE)
Historical Stock Chart
From Jun 2024 to Jul 2024
PURE Bioscience (PK) (USOTC:PURE)
Historical Stock Chart
From Jul 2023 to Jul 2024